^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JSKN003

    i
    Other names: JSKN003, JSKN 003, JSKN-003
    Associations

    News

    Trials
    Company:
    Alphamab, CSPC Pharma
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    1year
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    New P3 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    gemcitabine • paclitaxel • docetaxel • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate • JSKN003
    over1year
    To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting | Phase classification: P1a/1b --> P1/2
    Enrollment open • Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 expression
    |
    JSKN003
    over1year
    To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=365, Not yet recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    HER-2 positive • HER-2 mutation • HER-2 expression • BRAF wild-type • HER-2 exon 19 mutation
    |
    JSKN003
    2years
    First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors (clinicaltrials.gov)
    P1, N=45, Recruiting, Alphamab (Australia) Co Pty Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    JSKN003
    over2years
    First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Alphamab (Australia) Co Pty Ltd.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    JSKN003